NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹560 Cr | ₹442 Cr | ₹356 Cr | ₹287 Cr | ₹277 Cr |
What is the latest Total Liabilities ratio of NGL FINECHEM ?
| Year | Total Liabilities |
|---|---|
| Mar2026 | ₹560 Cr |
| Mar2025 | ₹442 Cr |
| Mar2024 | ₹356 Cr |
| Mar2023 | ₹287 Cr |
| Mar2022 | ₹277 Cr |
How is Total Liabilities of NGL FINECHEM Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹560 Cr | 26.83 | |
| Mar2025 | ₹442 Cr | 24.29 | |
| Mar2024 | ₹356 Cr | 23.85 | |
| Mar2023 | ₹287 Cr | 3.67 | |
| Mar2022 | ₹277 Cr | - | |
Compare Total Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,801.2 Cr | -6.8% | -18.4% | 87% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,634.0 Cr | 1.7% | -1.4% | 21.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹241,576.0 Cr | 2% | 10.3% | 49.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,478.0 Cr | -0.4% | -0.5% | 38.6% | Stock Analytics | |
| CIPLA | ₹111,888.0 Cr | -0.5% | -2.5% | -10.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,322.1 Cr | -1.2% | 0% | -7.1% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -6.8% |
-18.4% |
87% |
| SENSEX | -1% |
-2.6% |
-4.1% |
You may also like the below Video Courses